title: Fluvastatin in the therapy of acute coronary syndrome: Rationale and design of a multicenter, randomized, double-blind, placebo-controlled trial (The FACS Trial)[ISRCTN81331696].
abstract: BACKGROUND: Activation of inflammatory pathways plays an important contributory role in coronary plaque instability and subsequent rupture, which can lead to the development of acute coronary syndrome (ACS). Elevated levels of serum inflammatory markers such as C-reactive protein (CRP) represent independent risk factors for further cardiovascular events. Recent evidence indicates that in addition to lowering cholesterol levels, statins also decrease levels of inflammatory markers. Previous controlled clinical trials reporting the positive effects of statins in participants with ACS were designed for very early secondary prevention. To our knowledge, no controlled trials have evaluated the potential benefits of statin therapy, beginning immediately at the time of hospital admission. A previous pilot study performed by our group focused on early initiation of cerivastatin therapy. We demonstrated a highly significant reduction in levels of inflammatory markers (CRP and interleukin-6). Based on these preliminary findings, we are conducting a clinical trial to evaluate the efficacy of another statin, fluvastatin, as an early intervention in patients with ACS. METHODS: The FACS-trial (Fluvastatin in the therapy of Acute Coronary Syndrome) is a multicenter, randomized, double-blind, placebo-controlled study evaluating the effects of fluvastatin therapy initiated at the time of hospital admission. The study will enroll 1,000 participants admitted to hospital for ACS (both with and without ST elevation). The primary endpoint for the study is the influence of fluvastatin therapy on levels of inflammatory markers (CRP and interleukin-6) and on pregnancy associated plasma protein A (PAPP-A). A combined secondary endpoint is 30-day and one-year occurrence of death, nonfatal myocardial infarction, recurrent symptomatic ischemia, urgent revascularization, and cardiac arrest. CONCLUSION: The primary objective of the FACS trial is to demonstrate that statin therapy, when started immediately after hospital admission for ACS, results in reduction of inflammation and improvement of prognosis. This study may contribute to new knowledge regarding therapeutic strategies for patients suffering from ACS and may offer additional clinical indications for the use of statins.
authors.affiliation: Department of Cardiology, University Hospital Motol and Charles University, 2nd Faculty of Medicine, Prague, Czech Republic. ostadal@yahoo.com.
authors.forename: Petr
authors.initials: P
authors.lastname: Ostadal
authors.forename: David
authors.initials: D
authors.lastname: Alan
authors.forename: Petr
authors.initials: P
authors.lastname: Hajek
authors.forename: Jiri
authors.initials: J
authors.lastname: Vejvoda
authors.forename: Martin
authors.initials: M
authors.lastname: Mates
authors.forename: Peter
authors.initials: P
authors.lastname: Blasko
authors.forename: Josef
authors.initials: J
authors.lastname: Veselka
authors.forename: Milan
authors.initials: M
authors.lastname: Kvapil
authors.forename: Jiri
authors.initials: J
authors.lastname: Kettner
authors.forename: Martin
authors.initials: M
authors.lastname: Wiendl
authors.forename: Ondrej
authors.initials: O
authors.lastname: Aschermann
authors.forename: Josef
authors.initials: J
authors.lastname: Slaby
authors.forename: Eduard
authors.initials: E
authors.lastname: Nemecek
authors.forename: Frantisek
authors.initials: F
authors.lastname: Holm
authors.forename: Marek
authors.initials: M
authors.lastname: Rac
authors.forename: Milan
authors.initials: M
authors.lastname: Macek
authors.forename: Jana
authors.initials: J
authors.lastname: Cepova